- Home
- DTST vs INKT Comparison
DTST vs INKT Comparison
Compare DTST & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- INKT
- Stock Information
- Founded
- DTST 2001
- INKT 2017
- Country
- DTST United States
- INKT United States
- Employees
- DTST N/A
- INKT N/A
- Industry
- DTST EDP Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- DTST Technology
- INKT Health Care
- Exchange
- DTST Nasdaq
- INKT Nasdaq
- Market Cap
- DTST 28.2M
- INKT 28.8M
- IPO Year
- DTST N/A
- INKT 2021
- Fundamental
- Price
- DTST $3.53
- INKT $62.86
- Analyst Decision
- DTST
- INKT Strong Buy
- Analyst Count
- DTST 0
- INKT 2
- Target Price
- DTST N/A
- INKT $37.50
- AVG Volume (30 Days)
- DTST 30.5K
- INKT 2.4M
- Earning Date
- DTST 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- DTST N/A
- INKT N/A
- EPS Growth
- DTST N/A
- INKT N/A
- EPS
- DTST 0.02
- INKT N/A
- Revenue
- DTST $25,219,312.00
- INKT N/A
- Revenue This Year
- DTST $12.57
- INKT N/A
- Revenue Next Year
- DTST $9.29
- INKT N/A
- P/E Ratio
- DTST $148.58
- INKT N/A
- Revenue Growth
- DTST N/A
- INKT N/A
- 52 Week Low
- DTST $2.93
- INKT $4.56
- 52 Week High
- DTST $6.53
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- DTST 49.28
- INKT 57.39
- Support Level
- DTST $3.33
- INKT $6.80
- Resistance Level
- DTST $3.56
- INKT $7.88
- Average True Range (ATR)
- DTST 0.13
- INKT 0.40
- MACD
- DTST 0.02
- INKT 0.02
- Stochastic Oscillator
- DTST 70.00
- INKT 58.86
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.